Swiss National Bank’s Amicus Therapeutics FOLD Stock Holding History

Swiss National Bank’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.97M	Buy	551,000 +4,000	+0.7%	+$57.3K	﹤0.01%	1084
2025 Q4	$7.79M	Buy	547,000 +69,300	+15%	+$681K	﹤0.01%	1103
2025 Q3	$3.76M	Buy	477,700 +19,000	+4%	+$135K	﹤0.01%	1483
2025 Q2	$2.63M	Buy	458,700 +24,500	+6%	+$158K	﹤0.01%	1636
2025 Q1	$3.54M	Sell	434,200 -3,300	-0.8%	-$30.5K	﹤0.01%	1447
2024 Q4	$4.12M	Buy	437,500 +3,200	+0.7%	+$33.3K	﹤0.01%	1450
2024 Q3	$4.64M	Hold	434,300	–	–	﹤0.01%	1373
2024 Q2	$4.31M	Hold	434,300	–	–	﹤0.01%	1364
2024 Q1	$5.12M	Buy	434,300 +9,900	+2%	+$127K	﹤0.01%	1286
2023 Q4	$6.02M	Sell	424,400 -44,800	-10%	-$509K	﹤0.01%	1174
2023 Q3	$5.71M	Buy	469,200 +7,600	+2%	+$98K	﹤0.01%	1201
2023 Q2	$5.8M	Buy	461,600 +6,800	+1%	+$80.7K	﹤0.01%	1221
2023 Q1	$5.04M	Sell	454,800 -53,200	-10%	-$656K	﹤0.01%	1267
2022 Q4	$6.2M	Buy	508,000 +9,700	+2%	+$109K	﹤0.01%	1186
2022 Q3	$5.2M	Buy	498,300 +3,600	+0.7%	+$40.1K	﹤0.01%	1250
2022 Q2	$5.31M	Sell	494,700 -32,400	-6%	-$267K	﹤0.01%	1285
2022 Q1	$4.99M	Buy	527,100 +56,800	+12%	+$533K	﹤0.01%	1436
2021 Q4	$5.43M	Hold	470,300	–	–	﹤0.01%	1416
2021 Q3	$4.49M	Buy	470,300 +4,200	+0.9%	+$43K	﹤0.01%	1540
2021 Q2	$4.49M	Sell	466,100 -69,800	-13%	-$681K	﹤0.01%	1573
2021 Q1	$5.29M	Buy	535,900 +9,300	+2%	+$144K	﹤0.01%	1426
2020 Q4	$12.2M	Buy	526,600 +1,000	+0.2%	+$20.5K	0.01%	828
2020 Q3	$7.42M	Sell	525,600 -43,200	-8%	-$630K	0.01%	955
2020 Q2	$8.58M	Buy	568,800 +74,600	+15%	+$909K	0.01%	840
2020 Q1	$4.57M	Buy	494,200 +6,800	+1%	+$64.6K	﹤0.01%	982
2019 Q4	$4.75M	Buy	487,400 +53,300	+12%	+$488K	﹤0.01%	1185
2019 Q3	$3.48M	Buy	434,100 +17,900	+4%	+$194K	﹤0.01%	1320
2019 Q2	$5.19M	Buy	416,200 +71,200	+21%	+$903K	0.01%	1093
2019 Q1	$4.69M	Buy	345,000 +10,600	+3%	+$129K	0.01%	1121
2018 Q4	$3.2M	Buy	334,400 +5,700	+2%	+$62.7K	﹤0.01%	1259
2018 Q3	$3.97M	Buy	328,700 +5,800	+2%	+$81.1K	﹤0.01%	1262
2018 Q2	$5.04M	Hold	322,900	–	–	0.01%	1089
2018 Q1	$4.86M	Buy	322,900 +70,700	+28%	+$1.08M	0.01%	1068
2017 Q4	$3.63M	Buy	252,200 +11,900	+5%	+$163K	﹤0.01%	1264
2017 Q3	$3.62M	Buy	240,300 +30,000	+14%	+$397K	﹤0.01%	1226
2017 Q2	$2.12M	Hold	210,300	–	–	﹤0.01%	1562
2017 Q1	$1.5M	Hold	210,300	–	–	﹤0.01%	1765
2016 Q4	$1.04M	Buy	210,300 +27,700	+15%	+$192K	﹤0.01%	2005
2016 Q3	$1.35M	Hold	182,600	–	–	﹤0.01%	1775
2016 Q2	$997K	Hold	182,600	–	–	﹤0.01%	1966
2016 Q1	$1.49M	Buy	182,600 +42,400	+30%	+$300K	﹤0.01%	1635
2015 Q4	$1.36M	Buy	140,200 +5,100	+4%	+$46K	﹤0.01%	1591
2015 Q3	$1.89M	Buy	135,100 +17,000	+14%	+$267K	﹤0.01%	1354
2015 Q2	$1.67M	Buy	118,100 +38,700	+49%	+$465K	﹤0.01%	1432
2015 Q1	$864K	Buy	79,400 +16,000	+25%	+$141K	﹤0.01%	1841
2014 Q4	$527K	Buy	+63,400	New	+$435K	﹤0.01%	2144

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Swiss National Bank's FOLD Position: Q1 2026 in Review

Swiss National Bank increased its Amicus Therapeutics (FOLD) stake by 0.73% in Q1 2026, buying an estimated $57.3K and bringing the position to 551,000 shares worth $7.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1084.

Swiss National Bank first reported a position in FOLD in Q4 2014 and has held it in 46 quarters since. The position peaked at $12.2M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Swiss National Bank held 551,000 shares of Amicus Therapeutics worth $7.97M as of Q1 2026.
Swiss National Bank bought 4,000 Amicus Therapeutics shares in Q1 2026, an estimated $57.3K.
Amicus Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1084 holding.
Swiss National Bank first reported a position in Amicus Therapeutics in Q4 2014 and has held it in 46 quarters since.
Swiss National Bank's Amicus Therapeutics position peaked at $12.2M in Q4 2020.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.